Andrea Wang-Gillam, MD, PhD of Washington University School of Medicine @WUSTLmed discusses the phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer presented at this year’s AACR Annual Meeting.
Andrea Wang-Gillam, MD on Phase I Study of Defactinib Combined with Pembrolizumab and Gemcitabine #AACR #AACR20 @WUSTLmed
